MEDICAL IP unveils 'Medical Metaverse' for the first time at ‘RSNA 2021’

▶ Disclosure of virtual/augmented/extended reality technology that implements human body information based on medical images in Metaverse

▶ Goal of entering the global market by introducing ‘TiSepX’, an X-ray quantification solution, and ‘DeepCatch’, an automatic body composition analysis solution

MEDICAL IP is drawing attention by first releasing Medical Metaverse to the radiology academia and industry officials around the world.

MEDICAL IP participated in 'RSNA 2021 (11/28~12/2)', the largest radiology conference in North America, held in Chicago until December 2, and unveiled medical image-based AI analysis solutions including medical metaverse.

MEDICAL IP is a medical image segmentation, analysis, 3D modeling, and metaverse software 'MEDIP' based on medical image AI segmentation technology ▲DeepCatch, an AI body composition automatic analysis software based on CT ▲X-ray quantification and treatment monitoring It unveiled a diverse lineup of medical AI products such as the platform 'TiSepX'.


This technology helps to determine the surgical route accurately and precisely by realizing the patient's organs in a specific diseased area in augmented reality during surgery, or to accurately grasp and dissect the patient's internal information without a cadaver. It is a solution that enables the utilization of human body information on the metaverse, such as implementing organs in a virtual space to make it possible.

The company said, “In the process of planning and executing surgery, if medical staff visually check organs and lesions with augmented reality technology, the safety and stability of surgery can be greatly improved. In the future, we are preparing for licensing to expand the introduction of medical fields in the future.”

In addition, through this AI Theater session, Professor Soonho Yoon of the Department of Radiology at Seoul National University Hospital presented 'The metaverse based on AI image segmentation, the development of patient-centered radiology realized by 3D printing (AI Image Segmentation-driven AI Innovations, the High-throughput) Under the theme of 'Metaverse, and 3D Printing: Working toward the Goal of Patient-centered Radiology', Medical IP announced that AI medical image segmentation technology has scalability to various platforms.

A lecture by Professor Soon-Ho Yoon, Department of Radiology, Seoul National University Hospital, held at the RSNA ‘AI Theater’ session

Among the several products introduced through this presentation, T-Sep, which can segment, analyze, and quantify various lung diseases on chest X-ray, has received high attention as an innovative technology that did not exist before. T-Sep, which can quantify and analyze various lung diseases in two dimensions in two-dimensional X-rays, newly introduced ‘Lung Volumetry’ technology that quantifies lung volume through RSNA. This is a technology that can accurately measure the entire three-dimensional lung volume in a non-face-to-face manner using existing chest X-rays without lung function tests or CT scans, and it is expected to greatly help in the ease of treatment and monitoring of lung capacity.

Regarding this, Sang-joon Park CEO of MEDICAL IP said, “All AI technologies of MEDICAL IP have been developed to add new value to medical images and directly contribute to saving patients’ lives. We introduced innovative technologies that can provide advanced medical services throughout the entire life cycle of disease prediction, prevention, and treatment, and using these as a bridgehead, we plan to strengthen overseas marketing so that the introduction of our technology can be expanded to medical fields around the world. “, he said confidently.


Jul 19 / 2024

MEDICAL IP Signs MEDIP Box Supply Agreement with Africa Future Foundation

Jul 1 / 2024

Into the era of Avatar Medical Education.. Is VR becoming the land of opportunity for medical industry?

Jun 28 / 2024

Medical Education Lineup based on virtual and augmented reality unveiled at METAVERSE EXPO 2024


Questions on our public relations?

Ask us now.